Metabolic disorders can take many forms, with obesity and diabetes being the most common. The worldwide prevalence of obesity has nearly tripled between 1975 and 2016. Once considered a high-income country problem, obesity is now on the rise even in low- and middle-income countries. Overall, about 13% of the world’s adult population was considered obese in 2016. Of that 13%, 11% were men and 15% were women. In that same year, it was estimated that 41 million children under the age of 5, and 340 million children and adolescents aged 5 to 19, were considered overweight or obese.

Click here to download a readable, PDF version of Issue 5: https://www.altasciences.com/sites/default/files/2022-04/The-Altascientist_issue5_Metabolic_2022.pdf

Issue 5 was originally released in print in 2018.

CHAPTERS:

- 0:09 — Section 1: Current State of Metabolic Disorders

- 2:21 — Section 2: Ask the Expert — A Q&A with Altasciences' Ingrid Holmes, VP of Global Clinical Operations

- 5:40 — Section 3: An Epidemic Still on the Rise

- 7:53 — Section 4: Case Study

- 11:52 — Section 5: A Hidden Threat — Nanalcoholic Fatty Liver Disease

- 15:27 — Section 6: Recruitment Process and Patient Access for NASH Studies

Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.